Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10 Suppl
|
pubmed:dateCreated |
1992-10-20
|
pubmed:abstractText |
We used fibrin clot (FC) as a carrier of anticancer drug (AD) to provide a novel therapy for patients with serious malignant pleural effusion. After evacuating the pleural fluid, we enhanced an "FC-AD" formation in the pleural cavity of the patient to prevent this kind of effusion from reaccumulating. In an attempt to enhance FC-AD formation, we used two different procedures; either, fibrinogen/AD/G.T.XIII (procedure I) or fibrin glue/AD (procedure II). G.T.XIII is our newly devised compound drug, composed of biodegradable gelatin (G), thrombin (T) and a blood coagulation factor XIII (XIII). This therapy was termed "Bio-Adhesio-Chemo (BAC) therapy." We conducted BAC therapy 52 times on 44 patients using procedure I and 4 times on 4 patients using procedure II. Complete remission of the effusion was obtained, overall, in 83%, partial remission in 17%, and no non-effective case. The improvement of PS of the patients treated was 73%. Nineteen patients could be discharged with this therapy. Toxic effects with BAC therapy were within Grade 2 in all cases. We could favorably enhance FC-AD formation, in every case, by both procedure I and II. BAC therapy is very promising as a novel cancer chemopleurodesis for patients with malignant pleural effusion.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Factor XIII,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrin Tissue Adhesive,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrinogen,
http://linkedlifedata.com/resource/pubmed/chemical/Thrombin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0385-0684
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1640-3
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1530324-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1530324-Cisplatin,
pubmed-meshheading:1530324-Doxorubicin,
pubmed-meshheading:1530324-Drainage,
pubmed-meshheading:1530324-Drug Delivery Systems,
pubmed-meshheading:1530324-Factor XIII,
pubmed-meshheading:1530324-Fibrin Tissue Adhesive,
pubmed-meshheading:1530324-Fibrinogen,
pubmed-meshheading:1530324-Humans,
pubmed-meshheading:1530324-Neoplasms,
pubmed-meshheading:1530324-Pleural Effusion,
pubmed-meshheading:1530324-Thrombin
|
pubmed:year |
1992
|
pubmed:articleTitle |
[Locoregional therapy in patients with malignant pleural effusion--two different types of "BAC therapy"].
|
pubmed:affiliation |
Dept. of Surgery, Osaka National Hospital.
|
pubmed:publicationType |
Journal Article,
English Abstract
|